Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 5;8(9):3296-3313.
doi: 10.1021/acsptsci.5c00442. eCollection 2025 Sep 12.

Photoactivatable Cisplatin-Combretastatin-BODIPY Pt(IV) Prodrug for Dual-Action Light-Controlled Chemotherapy

Daniil V Spector  1 , Georgy Karetnikov  1 , Anna Bubley  1 , Roman A Akasov  2 , Yulia A Isaeva  1 , Tatiana V Egorova  2 , Alexander G Martynov  3 , Dmitry Bunin  3 , Dmitry A Skvortsov  1 , Daria Ipatova  1 , Alexander S Erofeev  4 , Petr V Gorelkin  4 , Vugara Mamed-Nabizade  4 , Vasilii S Kolmogorov  1   4 , Alexander N Vaneev  1   4 , Igor A Rodin  1 , Mikhail F Vokuev  1 , Yuri K Grishin  1 , Vitaly A Roznyatovsky  1 , Vita N Nikitina  1 , Elena K Beloglazkina  1 , Olga O Krasnovskaya  1
Affiliations

Photoactivatable Cisplatin-Combretastatin-BODIPY Pt(IV) Prodrug for Dual-Action Light-Controlled Chemotherapy

Daniil V Spector et al. ACS Pharmacol Transl Sci. .

Abstract

Herein, we designed, synthesized, and studied the activity of a novel dual-action red light-activatable Pt-(IV) prodrug BDP-Pt-CA4 with a BODIPY fluorophore and CA4 in axial positions, capable of light-controlled release of two chemotherapeutic drugs: cisplatin and combretastatin A4 (CA4). To the best of our knowledge, this is the first example of a dual-action photoactive Pt-(IV)-CA4 prodrug that releases two antiproliferative agents upon red light irradiation. The aim of this work was to demonstrate light-induced release of CA4 and cisplatin from the prodrug, occurring strictly on demand to reduce the overall toxicity of the drug and minimize the damaging effect on normal tissues. In addition to in vitro evidence of light-induced release of two chemotherapeutic agents, a controllable release of both drugs inside cancer cells was also proven. For the first time, a light-induced release of the tubulin polymerization inhibitor from a photoactivatable prodrug was observed via quantification of subtle changes in the mechanistic properties of cell surfaces via single-cell low-stress scanning ion conductance microscopy (SICM). Our results clearly demonstrate a perspective for photoactive Pt-(IV) prodrugs, confirming an ability to release the platinum agent "on demand", and to act as light-controlled dual-action chemotherapy.

Keywords: BODIPY; SICM; cisplatin; combretastatin; photoactivation; prodrug.

PubMed Disclaimer

References

    1. Wang D., Lippard S. J.. Cellular Processing of Platinum Anticancer Drugs. Nat. Rev. Drug Discovery. 2005;4(4):307–320. doi: 10.1038/nrd1691. - DOI - PubMed
    1. Petruzzella E., Sirota R., Solazzo I., Gandin V., Gibson D.. Triple Action Pt­(<scp > iv</Scp>) Derivatives of Cisplatin: A New Class of Potent Anticancer Agents That Overcome Resistance. Chem. Sci. 2018;9(18):4299–4307. doi: 10.1039/C8SC00428E. - DOI - PMC - PubMed
    1. Mikuła-Pietrasik J., Witucka A., Pakuła M., Uruski P., Begier-Krasińska B., Niklas A., Tykarski A., Książek K.. Comprehensive Review on How Platinum- and Taxane-Based Chemotherapy of Ovarian Cancer Affects Biology of Normal Cells. Cell. Mol. Life Sci. 2019;76(4):681–697. doi: 10.1007/s00018-018-2954-1. - DOI - PMC - PubMed
    1. Huang X., Huang R., Gou S., Wang Z., Liao Z., Wang H.. Combretastatin A-4 Analogue: A Dual-Targeting and Tubulin Inhibitor Containing Antitumor Pt­(IV) Moiety with a Unique Mode of Action. Bioconjugate Chem. 2016;27(9):2132–2148. doi: 10.1021/acs.bioconjchem.6b00353. - DOI - PubMed
    1. Petruzzella E., Braude J. P., Aldrich-Wright J. R., Gandin V., Gibson D.. A Quadruple-Action Platinum­(IV) Prodrug with Anticancer Activity Against KRAS Mutated Cancer Cell Lines. Angew. Chem. 2017;129(38):11697–11702. doi: 10.1002/ange.201706739. - DOI - PubMed